论文部分内容阅读
目的:观察美施康定直肠与口服两种途径给药控制中晚期癌痛的疗效及不良反应。方法:66例中晚期癌痛患者分为两组,即直肠给药,口服给药组,按需定时给药,30mg每12小时1次,必要时增加剂量,每次增加30mg,直至控制疼痛。结果:两组镇痛效果相似,直肠给药组总有效率87.9%,口服给药组90.9%,直肠给药组的不良反应明显较口服给药组减少。结论:美施康定是控制中晚期癌痛的理想药物,直肠给药不良反应小。
OBJECTIVE: To observe the curative effect and adverse reactions of mesylokacin rectally and orally in the control of middle and late stage cancer pain. Methods: Sixty-six patients with moderate and advanced stage cancer pain were divided into two groups: rectal administration, oral administration group, administration on schedule, 30 mg once every 12 hours, and if necessary, an increase of 30 mg each until the pain was controlled . Results: The analgesic effects of the two groups were similar. The total effective rate was 87.9% in the rectum group and 90.9% in the oral rectal group, and the adverse reactions in the rectal group were significantly lower than those in the oral group. Conclusion: Meishi Kangding is the ideal drug to control the cancer in the late stage, and the rectum adverse reaction is small.